

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM727253

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT		
NATURE OF CONVEYANCE:	Corrective Assignment to correct the Schedule B, Assignee address, and Assignor entity type previously recorded on Reel 007547 Frame 0025. Assignor(s) hereby confirms the Intellectual Property Legal Title Transfer Agreement (Premature).		
RESUBMIT DOCUMENT ID:	900674048		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Premature AB		01/31/2022	Company: SWEDEN
RECEIVING PARTY DATA			
Name:	Shire Human Genetic Therapies, Inc.		
Street Address:	300 Shire Way		
City:	LEXINGTON		
State/Country:	MASSACHUSETTS		
Postal Code:	02421		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	5043649	BEBRYSA	
Registration Number:	5044313	COZIPREM	
Registration Number:	3769767	PREMIPLEX	
Registration Number:	5044314	PREMVALO	
CORRESPONDENCE DATA			
Fax Number:	2127046288		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2127046125		
Email:	IPServicesNYC@troutman.com		
Correspondent Name:	Karl M. Zielaznicki, Esq.		
Address Line 1:	875 Third Avenue		
Address Line 2:	c/o IP Services NYC		
Address Line 4:	New York, NEW YORK 10022		
ATTORNEY DOCKET NUMBER:	255543.000019		
NAME OF SUBMITTER:	Karl M. Zielaznicki		
SIGNATURE:	/kmz/		

DATE SIGNED:	05/11/2022
---------------------	------------

Total Attachments: 6

source=ORIGINAL COVERSHEET assignment-tm-7547-0025#page1.tif

source=Takeda - Amendment to the Premacure IP Legal Title Transfer Agreement (002)#page1.tif

source=Takeda - Amendment to the Premacure IP Legal Title Transfer Agreement (002)#page2.tif

source=Takeda - Amendment to the Premacure IP Legal Title Transfer Agreement (002)#page3.tif

source=Takeda - Amendment to the Premacure IP Legal Title Transfer Agreement (002)#page4.tif

source=Takeda - Amendment to the Premacure IP Legal Title Transfer Agreement (002)#page5.tif

AMENDMENT
TO THE
INTELLECTUAL PROPERTY LEGAL TITLE TRANSFER AGREEMENT

(PREMACURE AB)

THIS AMENDMENT TO THE INTELLECTUAL PROPERTY LEGAL TITLE TRANSFER AGREEMENT (“Amendment”) is made and entered into on 31 January 2022, to be effective as of 24 November 2021 (“Effective Date”), by and between:

PREMACURE AB, a company organized and existing under the laws of Sweden and Luxembourg (“Assignor”),

and

SHIRE HUMAN GENETIC THERAPIES, INC., a corporation incorporated under the laws of State of Delaware, U.S.A. (“Assignee”).

(Assignor and Assignee are collectively referred to as the “Parties,” and each individually as a “Party”)

RECITALS

- A. The Parties entered into that certain Intellectual Property Legal Title Transfer Agreement effective as of the Effective Date (the “Agreement”), under which Assignor transferred, conveyed and assigned to Assignee all legal title to the Intellectual Property.
- B. The Parties desire to amend Exhibit B to the Agreement to delete a trademark that should not have been part of the scope of Intellectual Property transferred to Assignee under the Agreement, and revise the registered address of Assignee.
- C. Accordingly, the Parties wish to amend the Agreement in accordance with the terms and conditions herein.
- D. The Parties acknowledge and agree that this Amendment memorializes their original intentions and course of dealing as of the Effective Date.

Now, therefore, the Parties agree as follows:

AMENDMENT

- 1. As of the Effective Date, Exhibit B of the Agreement shall be removed and replaced in its entirety with Exhibit B as attached to this Amendment.
- 2. The Parties agree and acknowledge that Assignee’s registered address is 300 Shire Way, Lexington, Massachusetts 02421, U.S.A.



3. All capitalized terms in this Amendment shall have the meanings set forth in the Agreement, unless otherwise provided for herein.
4. All other terms and conditions of the Agreement shall remain in full force and effect without modification. Notwithstanding the foregoing, if any provision contained in this Amendment conflicts with any provision contained in the Agreement, the provision contained herein shall prevail.
5. The laws of the State of Delaware, U.S.A. (without reference to its principles of conflicts of law) shall govern the construction, interpretation and other matters arising out of or in connection with this Amendment (whether arising in contract, tort, equity or otherwise).
6. The Parties may execute this Amendment electronically and in multiple counterparts, each of which constitutes an original as against the party that signed it, and all of which together constitute one agreement. The signatures of both Parties need not appear on the same counterpart. The delivery of signed counterparts by facsimile or email transmission that includes a copy of the sending party's signature is as effective as signing and delivering the counterpart in person.

[Signature page follows]

The Parties have caused this Amendment to be executed by their duly authorized representatives with effect as of the Effective Date.

PREMACURE AB

SHIRE HUMAN GENETIC THERAPIES, INC.

By:  
Name: Barbara Lenzlinger Erik Adam
Title: Authorized signatory Authorized signatory
Date: 31 January 2022

By: _____
Name: _____
Title: _____
Date: _____

The Parties have caused this Amendment to be executed by their duly authorized representatives with effect as of the Effective Date.

PREMACURE AB

**SHIRE HUMAN GENETIC THERAPIES,
INC.**

By: _____

By: Krista Fiedler _____

Name: _____

Name: Krista Fiedler _____

Title: _____

Title: Assistant Treasurer _____

Date: _____

Date: 31 January 2022 _____